 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Up 30% today.10million shares traded, on the pinks. Press Release DNAPrint genomics, Inc. Expands Proprietary SNP Database SARASOTA, Fla.--(BUSINESS WIRE)--Aug. 22, 2000--DNAPrint genomics (Pink Sheets:DNAP) announced today the addition of the 2,000th candidate SNP to its Phenome(SM) database. The Phenome(SM) database contains a high-density map of SNP and haplotypes candidates for certain human genes of pharmacogenomic and cancer genetics value. This is believed to be one of the highest resolution SNP maps for genes of critical import to these two fields, and will be used by the company in conjunction with the public SNP database, as a platform upon which the companies work will be performed. The milestone of having made the 2,000th addition to this database allows the company the opportunity to share with its shareholders the value of the database and to highlight the DNAPrint genomics approach. The SNP consortium is slated to add a large collection of SNPs and corresponding sub-population allele frequencies to the public database. The value of this database is its widespread coverage of the human genome and its accessibility free of charge to researchers all over the world. The genome wide coverage of the public SNP database make it well suited for genome-wide linkage studies which will require a SNP, on average, every 3Kb of the human genome. These types of systematic studies will allow workers to identify important linkage disequilibria, or ``physical relationships'' between SNPs and disease/trait genes. Targeted Scanning is an alternative to systematic genome wide scanning, and focuses on surveying smaller number of genes in greater detail. The value of this approach can be appreciated from the decades of research that have contributed to our understanding of human disease. Studies of drug metabolism and cancer have shown a relatively small collection of genes, and gene types, to be responsible for a vast majority of problems. Pharmacogenetic studies have shown that polymorphism in xenobiotic metabolism proteins such as cytochrome p450 genes and N-acetyltransferases, among others to be associated with aberrant drug metabolism, resulting in some cases in hepatocellular toxicity or other ``side-effects''. Work in the field of cancer has shown that mutations in genes normally involved in these genes, as well as other basic tasks such as cell cycle regulation and DNA repair play important roles for this disease. Thus, certain phenotypic traits such as drug metabolism or cancer, are well suited for a targeted scanning study design. Notwithstanding its tremendous value, the pan-genome coverage of the public database comes at the expense of individual gene resolution. Since the public SNP database will contain relatively few SNPs for most human genes, there is and will remain a need for higher resolution SNP maps for many of the most ``important'' genes of clinical value. The public resources will contain no information on genetic haplotypes, or phase coupled genotype sets, which have considerable power for discovering genotype-phenotype associations. Further, the public SNP database will not be available publicly for some time. Lastly, most of the public SNP database will have come from healthy donors used for the human genome project and related efforts and therefore may biased against SNPs which play a role in human pathologies. Because of these anticipated deficiencies, DNAPrint genomics has been building its own candidate SNP and Haplotype database, called the Phenome(SM) database. The database focuses on many of the most ``important'' human drug metabolism and disease genes whose function is compromised in certain individuals who show drug side-effects or neoplastic disease. The database serves as a foundation for virtually any pharmacogenomic or cancer genetic study and is derived from two main sources: the application of a proprietary and automated set of data mining algorithms to the public (NCBI) EST/mRNA and Gene database, and through a process called ``re-sequencing'' where the large regions of the genes are actually sequenced from target patient groups. Resequencing involves obtaining long read sequences in contrast to single base, high-throughput SNP scoring which relies on the existence of an accurate SNP map such as the Phenome(SM) or public database. Candidate SNPs are accompanied by extensive annotation and 200bp of flanking DNA sequence that facilitates SNP scoring study design. SNPs for over 100 ``important'' human genes have been discovered, and approximately 20 high-quality candidate SNPs have been identified for each of these genes. The density of high quality SNP candidates within these genes is higher than the frequency of SNPs expected in the human genome from work by others (approximately 1 per 1000 base pairs). Further, the average gene in the Phenome(SM) database contains over 10 times the number of candidate SNPs that are currently available in the public database. SNPs for many of these genes have been discovered to be part of major population Haplotypes. The company will use this proprietary database as a foundation for its first SNP/Haplotype association and linkage disequilibrium studies for Pharmacogenomics and breast cancer. In addition to providing a proprietary database resource platform not available through the public SNP database, it enables the company to conduct detailed and high-resolution studies well in advance of those organizations awaiting the completion of the public database. The Phenome(SM) database recently recorded its 2000th entry, and is scheduled to add its 5,000th entry later this year. To the companies knowledge, it is one of the first databases of its kind to focus on resolution within ``important'' genes rather than across the entire genome, and will offer the company a decided advantage in its high-throughput SNP/Haplotype scoring studies. The company intends to copyright the database, and patent its components discovered to be associated with clinical pathologies as ``diagnomics'' products. About DNAPrint genomics DNAPrint genomics, Inc. provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.dnaprint.com. Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those contained in such statements. Factors that could cause or contribute to such differences include unexpected shortages of critical components, rescheduling or cancellation of customer orders, the timing and market acceptance of new product introductions by the Company and its competitors, and general competition and price pressures in the marketplace -------------------------------------------------------------------------------- Contact: DNAPrint genomics, Inc., Sarasota For scientific inquiries please contact: Dr. Tony Frudakis, 941/351-4543 or All other inquiries please contact: Richard Craig Hall, 941/341-0136 | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |